VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

SARS-CoV Salmonella-tPA-S DNA vaccine
Vaccine Information
  • Vaccine Name: SARS-CoV Salmonella-tPA-S DNA vaccine
  • Target Pathogen: SARS-CoV
  • Target Disease: Severe Acute Respiratory Syndrome (SARS)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein (Woo et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Description:
    • Detailed Gene Information: Click Here.
  • Immunization Route: Oral
  • Description: oral live-attenuated auxotrophic S. typhimurium aroA strain SL7207 that contained tPA-optimize800 DNA vaccine (Woo et al., 2005)
Host Response

Mouse Response

  • Host Strain: Balb/c (H-2d) (Woo et al., 2005)
  • Host age: 6-8 weeks (Woo et al., 2005)
  • Host gender: Male (Woo et al., 2005)
  • Vaccination Protocol: oral injection of 6e9 live attenuated Salmonella typhimurium that underwent transfection of tPA-S (Woo et al., 2005)
  • Immune Response: neutralizing antibody titers of <1:20–1:160, lymphocyte proliteration, production of IFN-γ, production of IL-4 (48hrs) (Woo et al., 2005)
References
Woo et al., 2005: Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005; 23(42); 4959-4968. [PubMed: 15993989].